Global Footprint Global footprint with four fully owned, harmonized laboratory facilities across the US, Europe, Singapore, and China, including Shanghai expansion. This scale enables seamless multi-regional trials with consistent data standards. Position as a single partner for end-to-end central laboratory testing and global data harmonization to accelerate trial timelines.

Biomarker Mastery Broad biomarker and translational testing capabilities, including integrated safety assessments, biomarker assay development and validation, exploratory and endpoint biomarker analysis, molecular testing, global flow cytometry, pathology, and vaccine development support. These capabilities enable cross-sell into oncology, immuno-oncology, infectious disease, and vaccine programs.

Infectious Disease Readiness RSV testing capacity expansion and related infectious disease capabilities, including collaboration with Viracor Biopharma and Shanghai operations, demonstrate rapid scale and geographic reach. This positions Eurofins Central Laboratory to support respiratory disease trials and vaccine studies across regions.

Data Quality Edge Committed to high-quality, globally harmonized data and expert scientific guidance to facilitate smoother trial execution. This data integrity and regulatory-ready reporting capability creates upsell opportunities for data management, analytics, and quality assurance services across trials.

Strategic Partnerships Proven collaborations and growth momentum, such as the Alphora alliance and ongoing expansions, indicate strong integration potential within the Eurofins ecosystem for end-to-end services from discovery through development and analytics. This enables cross-selling opportunities to biopharma and CROs seeking a scalable central laboratory partner.